In a November 20, 2026 update for World Children’s Day, the WHO-hosted Global Accelerator for Paediatric Formulations Network (GAP-f) described its work to improve the development of medicines designed for children—and the gaps that remain in getting those medicines to them.
GAP-f’s 2025–2030 Strategic Roadmap includes a “30 by ’30” commitment: assess priorities across 10 high-burden diseases, accelerate 10 priority medicines, and strengthen paediatric medicines ecosystems in 10 countries by 2030. These are goals, not completed outcomes.
The network uses WHO’s Paediatric Drug Optimization process to identify medicines and formulations that address gaps in children’s prevention and treatment. It also works with partners to strengthen clinical research, including mapping trial-site capacity and supporting study designs that can produce evidence on medicines’ safety, efficacy and use in children.
Development alone does not ensure access. GAP-f said it works with WHO departments, countries and other partners to identify barriers to obtaining age-appropriate medicines. In May 2026, WHO and GAP-f partners held a South-East Asia regional workshop with stakeholders from four pilot countries to discuss challenges and possible solutions.
The update describes ongoing priorities and planned resources; it does not establish that the roadmap’s targets have been met or that access has improved for every child.